CLINICAL TRIALS PROFILE FOR CANCIDAS

All Clinical Trials for CANCIDAS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00105144 ↗	Study of Micafungin in Patients With Invasive Candidiasis or Candidemia	Completed	Astellas Pharma Inc	Phase 3	2004-09-01	The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
NCT00388167 ↗	Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Completed	GTEI		2004-03-01	We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00388167 ↗	Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Completed	SEMICYUC		2004-03-01	We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00388167 ↗	Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection	Completed	PETHEMA Foundation		2004-03-01	We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).
NCT00404092 ↗	Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis	Completed	University of Cologne	Phase 2	2006-10-01	This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.
NCT00413218 ↗	Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections	Completed	Basilea Pharmaceutica	Phase 3	2007-03-08	The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

Clinical Trial Conditions for CANCIDAS

Condition Name

Condition Name for CANCIDAS
Intervention	Trials
Fungal Infection	7
Mycoses	5
Candidemia	5
Fungemia	4

Condition MeSH

Condition MeSH for CANCIDAS
Intervention	Trials
Mycoses	14
Infections	8
Infection	8
Candidiasis	7

Clinical Trial Locations for CANCIDAS

Trials by Country

Trials by Country for CANCIDAS
Location	Trials
United States	151
Canada	25
China	15
Spain	15
Brazil	8

Trials by US State

Trials by US State for CANCIDAS
Location	Trials
Michigan	8
California	6
Texas	6
Pennsylvania	6
Ohio	6

Clinical Trial Progress for CANCIDAS

Clinical Trial Phase

Clinical Trial Phase for CANCIDAS
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	8
Phase 2	5

Clinical Trial Status

Clinical Trial Status for CANCIDAS
Clinical Trial Phase	Trials
Completed	13
Active, not recruiting	2
Terminated	2

Clinical Trial Sponsors for CANCIDAS

Sponsor Name

Sponsor Name for CANCIDAS
Sponsor	Trials
Astellas Pharma Inc	3
Merck Sharp & Dohme Corp.	2
National Cancer Institute (NCI)	2

Sponsor Type

Sponsor Type for CANCIDAS
Sponsor	Trials
Other	14
Industry	12
NIH	3